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a b s t r a c t  
Background: Case reports and epidemiologic studies have reported a relation between different vaccines 
including measles, rubella, mumps and Guillain-Barre syndrome (GBS). In this study we investigated
relation between receiving measles and/or rubella vaccines and occurrence of GBS after national immu­
nization campaign in 2003 in Iran. 
Materials and methods: We used the national surveillance system for acute ﬂaccid paralysis from the
beginning of 2002 to the end of 2004 and studied the incidence of GBS disease among 5–14-year-old
children. The 3-year time span of the study was divided into ﬁfteen 10 weeks intervals and the number of
reported and conﬁrmed GBS case reports in each time period was analyzed supposing their distribution 
was according to Poisson distribution. 
Results: From 2002 through 2004 there were 370 patients conﬁrmed GBS case reports among persons
5–14 years of age. The annual incidence in this age group remained relatively constant over the 3-year
period and ranged from 0.65 per 100,000 population in 2004 to 0.76 in 2003. The estimated average annual
incidence of GBS in persons <15 years of age was 1/100,000 (CI 95%: 0.88–1.13), and 0.7/100,000 in persons
5–14 years of age (CI 95%: 0.58–0.83). No obvious seasonal pattern in GBS occurrence was observed. The
mean number of GBS patients during each 10 week study interval was 23.8. Twenty-ﬁve patients with GBS
were reported in the time period which coincided with national immunization campaign. The probability
of occurring ≥25 cases of GBS in that time period according to Poison distribution with expected case
numbers of 23-8 is equal to 0.43 (p = 0.43). 
Conclusion: The yearly incidence rate of GBS in this study was similar to other studies. According to our 
results, there was no increase in GBS Incidence in the 4 weeks national Immunization campaign and 6 
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. Introduction 
Guillain-Barre syndrome (GBS) is an autoimmune disorder char­
cterized by a group of diverse clinical and pathologic ﬁndings. 
pidemiologic studies in Europe, the United States and Australia 
eport a GBS incidence rate 1/100,000 per year. The etiology of 
BS is unknown yet, but several events have been observed which 
ccur before development of disease including acute infections and 
mmunizations. Numerous studies have documented an associa­
ion of GBS and selected infections and it has been hypothesized 
hat selected infections may activate immune system, leading to 
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ross-reaction with myelin leading to demyelinization and axonal 
egeneration [1]. 
The most frequent infection associated with disease is gas­
roenteritis caused by Campylobacter jejune. Overall, approximately 
0% of GBS patients report diarrhea before developing GBS; 
ositive serology or culture exists in 26–36% of these patients. 
ytomegalovirus (CMV) infection is also associated with GBS and is 
he second prevalent infection prior to GBS occurrence. In different 
tudies between 5 to 22 percent of GBS cases show the evidences 
f CMV infection [1]. Several case studies and epidemiologic stud­
es report a relation between GBS and receipt of different vaccines 
ncluding rabies, poliomyelitis [2,3], inﬂuenza [4,5], measles [6], 
umps-measles-rubella(MMR) [7], tetanus toxoid containing vac­
ines [8]. The American Academy of Neurology reported nearly a 
housand cases of GBS to CDC between 1978 and 1979, of which only 
5059 A. Esteghamati et al. / Vaccine 26 (2008) 5058–5061 
Table 1 
Number of approved GBS in 5–14 years-old Iranians during the study and the GBS annual incidence rate 
Time period Year 2002 Year 2003 Year 2004 
December 13 11 10 
January 3 4 11 
February 9 11 9 
March 8 14 13 
April 19 8 6 
May 11 17 11 
June 6 15 7 
July 9 15 15 
August 9 11 3 
September 15 11 7 
October 6 7 15 
November 12 11 7 
Whole year 121 135 114 
Annual incidence per 100000 0.68 0.76 0.65 
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pI 95%* 0.57–0.82 
* CI 95% has been calculated using exact binomial method. 
5 cases (∼4.5%) had history of an immunization during 8 weeks 
efore GBS occurrence [9]. 
Later review studies did not ﬁnd a causal relation between injec­
ion of measles or measles-rubella vaccines and development of 
BS [10,11]. In a 5-year study in Finland in which admitted cases of 
BS to hospitals have been compared to other recipients of measles, 
ubella, and mumps vaccines, no causal relation was seen between 
eceiving any of these vaccines and occurrence of disease [12]. In
he Australian National Immunization campaign against measles, 
ubella, and mumps in 1998, nearly two million school age per­
ons were vaccinated; only three patients developed GBS consistent 
ith previous rates in Australia and UK [13]. Several studies in dif­
erent countries reported incidence of GBS as 0.4–2/100,000 [14,15]. 
This study was conducted to assess any relation between 
easles and/or rubella vaccination in national immunization cam­
aign and occurrence of GBS. From 6 December 2003 to 3 January 
004, the Ministry of Health and Medical Education in Iran con­
ucted a nationwide immunization campaign targeting 33,579,082 
eople between the ages of 5–25 years with a combined measles 
edmonston-zagreb strain) and rubella (wistar ra 27/3 strain) live 
ttenuated vaccine; 98% of the target population were vaccinated. 
e hypothesized that if there is a causative relation between 
mmunization against measles and/or rubella and GBS, it’s inci­
ence would increase after the immunization campaign period 
omparing to the time before the campaign. 
a
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Fig. 1. Monthly distribution of 5–14-year-old patients with Guillain-0.64–0.90 0.53–0.77 
. Materials and methods 
In this study we used national surveillance system for acute ﬂac­
id paralysis data from the beginning of 2002 to the end of 2004. 
his system is established to detect occurrence of poliomyelitis 
ases. One of differential diagnoses for acute ﬂaccid paralysis is 
BS, and case deﬁnition in this system is the occurrence of any 
cute ﬂaccid paralysis in persons <15 years of age without any 
istory of trauma. All case-reports are gathered from health cen­
ers, medical ofﬁces, clinics and registered in a standardized format 
ccording to guidelines from the World Health Organization pro­
ocols. These data are categorized using guidelines through special 
ommittees of the universities of medical sciences (UMSs) across 
he country, and ﬁnally veriﬁed by a national committee in Center 
or Disease Control. Data for all acute ﬂaccid paralyses cases in all 
MSs are entered into a computerized database for analysis and 
eporting. The occurrence of any GBS case is veriﬁed by national 
ommittee. 
As the common age range between immunization campaign 
gainst measles and rubella (5–25 years olds) and acute ﬂaccid 
aralysis surveillance system (under 15 year-olds) was 5–14-years 
ge group, we compared the national incidence of GBS in this age 
roup during the immunization campaign with the other time peri­
ds. The population of persons under 15 years of age and persons 
–14 years of age were derived from estimates of Iranian Center for 
Barre syndrome in Iran from January 2002 to December 2004. 
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Table 2 
Trends in Guillan-Barre in 5–14-year-old children in each 10-weeks time period from 
January 2002 through September 2004 
10-weeks time period Number of GBS cases 
January 5–March 16, 2002 17 
March 16–May  24, 2002  31  
May 25–August 2, 2002 18 
August 3–October 11, 2002 26 
October 12–December 20, 2002 23 
December 21, 2002–February 28, 2003 20 
March 1–May 9, 2003 27 
May 10–July 18, 2003 40 
July 19–September 26, 2003 24 
September 27–December 5, 2003 20 
December 6, 2003–February 13, 2004 25 
February 14–April 24, 2004 22 
April 25–July 3, 2004 20 
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Auly 4–September 11, 2004 20 
ep 12–November 20, 2004 24 
otal 357 
tatistics for this age groups for the year 2004, which was mode 
f time duration of the study. According to these estimates, the 
opulations for these age groups were 26,259,600 and 17,683,680, 
espectively. The time of onset of paralysis symptoms was proposed 
s the time basis for age of affected persons. 
The number of reported and approved GBS patients 5–14 years 
f age in each month were used to evaluate any changes in GBS 
ncidence. We compared these data with expected incidence rates 
n the same time period according to Poisson distribution to iden­
ify if there was an increase in GBS incidence in the time period of 
ational immunization campaign compared to similar time periods 
efore and after the campaign. As GBS is rare and study population 
as very large, the distribution of GBS cases in the studied time 
eriod was assumed to be according Poisson distribution. A 6 weeks 
eriod has been considered as maximum time between immuniza­
ion and the onset of paralysis symptoms (the latent period of GBS) 
12,16,17]. Taking into account that the national immunization cam­
aign lasted for 4 weeks, a 10-weeks time periods was used as 
he interval in which GBS cases were compared to the other time 
eriods. In the time span of the study, we calculated GBS disease 
ates for ﬁfteen 10-weeks time periods from 5 January 2002 to 20 
ovember 2004. 
The mean number of GBS cases in all 10 weeks periods was con­
idered as expected number of GBS cases in Poisson distribution. 
he exact Poisson measure has been used to determine the con­
dence interval of the annual incidence of GBS. Population of the 
arget group (denominator of the fraction) was considered equal to 
ne ﬁfth of annual population of the target group. 
. Results 
In the time span of the study, 1218 reports of acute ﬂaccid paral­
sis were identiﬁed including 785 patients (∼64.5%) classiﬁed as 
aving GBS. During this time interval, there were 370 patients con­
rmed GBS case reports among persons 5–14 years of age. The 
nnual incidence in this age group remained relatively constant 
ver the 3 year period and ranged from 0.65 per 100,000 pop­
lation in 2004 to 0.76 in 2003 (Table 1). The estimated average 
nnual incidence of GBS in persons <15 years of age is 1/100,000 
CI 95%: 0.88–1.13), and 0.7/100,000 in persons 5–14 years of age 
CI 95%: 0.58–0.83). No obvious seasonal pattern was seen in GBS 
ccurrence (Fig. 1). 
The mean number of GBS patients identiﬁed per 10-week period 
as 23.8 during the study period (Table 2). The highest reported 
ccurrence of GBS was for 10 May to 18 July 2003, before the immu­
o
o
r 26 (2008) 5058–5061 
ization campaign. Twenty-ﬁve patients with GBS were reported 
n the time period which coincided with national immunization 
ampaign. The probability of 25 cases of GBS occurring in the 
mmunization campaign including time period according to Pois­
on distribution with expected cases number of 23.8 is equal to 
.43 (p = 0.43). In the time period of the immunization campaign, 
he annualized incidence rate of GBS in 5–14-year-old children was 
.71/100,000, which is in concordance with expected incidence 
ate of 0.67/100,000 (CI 95%: 0.44–1) that was computed based 
n occurrence of 23.8 cases of GBS in each 10-weeks time period. 
hus, during the national immunization campaign, the number of 
eported cases of GBS was not more than expected incidence rate. 
. Discussion 
In this study, the annual incidence rate of GBS is similar to other 
tudies [18–21]. We observed no increase in GBS occurrence in 
he 4 week period of the national immunization campaign and 
he 6 week period following the campaign. In measles-rubella 
ass immunization campaign in Albania, 867,000 doses of vaccine 
ere administered to children 1–14 years of age; 1 case of GBS 
as reported with a GBS incidence rate of 0.12/100,000 (CI 95%: 
.003–0.64) [1,22]. 
In a 5 years study between 1982–1986 in Finland, the average 
nnual incidence rate of GBS after measles-mumps-rubella vacci­
ation reported as 0.93/100,000 in 1–12 years-old children [12]. 
When evaluating poliomyelitis surveillance system of four con-
ries in Latin America, Silveira et al. [16] estimated an average 
nnual incidence of GBS among children 5–14 years of age as 
.52/100,000 (CI 95%: 0.49–1.53). In this study in the 72 days time 
eriod containing 1-month measles mass vaccination and 6 weeks 
fterwards 97 cases of GBS were reported in Argentina, Brazil, Chile, 
nd Colombia, which was not signiﬁcantly different from expected 
ccurrence of GBS (93 cases) presuming Poisson distribution of GBS 
ccurrence in 72 days time periods. 
In a case-control study for evaluating risk factors of GBS occur­
ence, Liu et al. did not ﬁnd any relation between vaccination and 
ccurrence of GBS [23]. 
The above mentioned studies have used different methods to 
ssess any relationship or causation between measles and rubella 
accination and GBS occurrence in different age groups among chil­
ren. Our results were in concordance in time periods and similarly 
ound no relation between vaccination and occurrence of GBS. 
Since this study, as most of other similar studies, used acute 
accid paralysis surveillance system data, the validity (sensitivity 
nd speciﬁcity) of the surveillance system would have a signiﬁ­
ant inﬂuence on the ﬁndings. The World Health Organization has 
uggested reporting 1 or more cases of acute ﬂaccid paralysis per 
00,000 under 15 years old children as evolution land mark for 
ensitivity of such a surveillance system [24]. In Iran average of this 
ndex is 1.6 in each year of the study which is acceptable. Show­
ng a causative relation between measles and rubella vaccination, 
nd the occurrence of GBS needs prospective studies and follow up 
f probable complications of the vaccines. Therefore, we propose 
recise analysis of immunization complication registration system 
ata while controlling variables such as symptoms of infections like 
iarrhea and respiratory infections, and etc. 
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